Literature DB >> 16236963

Renal failure secondary to acute tubular necrosis: epidemiology, diagnosis, and management.

Namita Gill1, Joseph V Nally, Richard A Fatica.   

Abstract

Acute tubular necrosis (ATN) is a form of acute renal failure (ARF) that is common in hospitalized patients. In critical care units, it accounts for about 76% of cases of ARF. Despite the introduction of hemodialysis > 30 years ago, the mortality rates from ATN in hospitalized and ICU patients are about 37.1% and 78.6%, respectively. The purpose of this review is to discuss briefly the cause, diagnosis, and epidemiology of ARF, and to review in depth the clinical trials performed to date that have examined the influence of growth factors, hormones, antioxidants, diuretics, and dialysis. In particular, the role of the dialysis modality, dialyzer characteristics, and dosing strategies are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236963     DOI: 10.1378/chest.128.4.2847

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  31 in total

1.  Safety and diagnostic yield of renal biopsy in the intensive care unit.

Authors:  Jean-François Augusto; Vincent Lassalle; Pierre Fillatre; Dominique Perrotin; Ferhat Meziani; Maleka Schenck-Dhif; Pierre Edouard Bollaert; Damien du Cheyron; Gaetan Beduneau; Christophe Vinsonneau; Christophe Guitton; Nicolas Lerolle
Journal:  Intensive Care Med       Date:  2012-07-10       Impact factor: 17.440

2.  Endocrine disruptor vinclozolin induced epigenetic transgenerational adult-onset disease.

Authors:  Matthew D Anway; Charles Leathers; Michael K Skinner
Journal:  Endocrinology       Date:  2006-09-14       Impact factor: 4.736

3.  Postconditioning attenuates renal ischemia-reperfusion injury by mobilization of stem cells.

Authors:  Xiaohua Tan; Ruili Yin; Yan Chen; Dan Gao; Xiuying Zhang
Journal:  J Nephrol       Date:  2015-02-06       Impact factor: 3.902

4.  Catalpol protects mice against renal ischemia/reperfusion injury via suppressing PI3K/Akt-eNOS signaling and inflammation.

Authors:  Jili Zhu; Xinghua Chen; Huiming Wang; Qi Yan
Journal:  Int J Clin Exp Med       Date:  2015-02-15

5.  Depletion of Gut Microbiota Protects against Renal Ischemia-Reperfusion Injury.

Authors:  Diba Emal; Elena Rampanelli; Ingrid Stroo; Loes M Butter; Gwendoline J Teske; Nike Claessen; Geurt Stokman; Sandrine Florquin; Jaklien C Leemans; Mark C Dessing
Journal:  J Am Soc Nephrol       Date:  2016-12-07       Impact factor: 10.121

6.  HCaRG accelerates tubular repair after ischemic kidney injury.

Authors:  Hiroyuki Matsuda; Julie L Lavoie; Louis Gaboury; Pavel Hamet; Johanne Tremblay
Journal:  J Am Soc Nephrol       Date:  2011-09-15       Impact factor: 10.121

7.  Hematopoietic stem cells derived from human umbilical cord ameliorate cisplatin-induced acute renal failure in rats.

Authors:  Rokaya H Shalaby; Laila A Rashed; Alaa E Ismaail; Naglaa K Madkour; Sherien H Elwakeel
Journal:  Am J Stem Cells       Date:  2014-09-05

8.  The tumor gene survivin is highly expressed in adult renal tubular cells: implications for a pathophysiological role in the kidney.

Authors:  Philipp Lechler; Xiaoqing Wu; Wanja Bernhardt; Valentina Campean; Susanne Gastiger; Thomas Hackenbeck; Bernd Klanke; Alexander Weidemann; Christina Warnecke; Kerstin Amann; Dirk Engehausen; Carsten Willam; Kai-Uwe Eckardt; Franz Rödel; Michael Sean Wiesener
Journal:  Am J Pathol       Date:  2007-11       Impact factor: 4.307

9.  Secular trends in severe renal failure associated with the use of new antimicrobial agents in critically ill surgical patients.

Authors:  M E Eichhorn; H Wolf; H Küchenhoff; M Joka; K-W Jauch; W H Hartl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-06       Impact factor: 3.267

10.  Haematopoietic stem cell migration to the ischemic damaged kidney is not altered by manipulating the SDF-1/CXCR4-axis.

Authors:  Ingrid Stroo; Geurt Stokman; Gwendoline J D Teske; Sandrine Florquin; Jaklien C Leemans
Journal:  Nephrol Dial Transplant       Date:  2009-02-16       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.